Mechanism of Action of Deucravacitinib
Introduction Deucravacitinib is an oral immunomodulatory drug marketed under the brand name Sotyktu. Pharmacologically, deucravacitinib is a selective tyrosine kinase 2 inhibitor, commonly called a TYK2 inhibitor. Psoriasis and psoriatic arthritis are immune-mediated inflammatory diseases involving abnormal cytokine signaling, T-cell activation, keratinocyte inflammation, synovial inflammation, enthesitis, and systemic immune dysregulation. Important inflammatory pathways include interleukin-23, … Read more
